Evidence map›Paper›PMID 36711991›Full record

ArticlebioRxiv : the preprint server for biology2023

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants.

Panke Qu, Julia N Faraone, John P Evans, Yi-Min Zheng, Claire Carlin, Mirela Anghelina, Patrick Stevens, Soledad Fernandez, Daniel Jones, Ashish Panchal and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 49 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Panke QuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Julia N FaraoneCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
John P EvansCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Yi-Min ZhengCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Claire CarlinDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA.
Mirela AnghelinaDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Patrick StevensDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Soledad FernandezDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Daniel JonesDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Ashish PanchalDepartment of Emergency Medicine, The Ohio State University Wexner Medical Center, Columbus, USA.
Linda J SaifCenter for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences, The Ohio State University, Wooster, OH 44691, USA.
Eugene M OltzDepartment of Microbial Infection and Immunity, The Ohio State University, Columbus, OH 43210, USA.
Kai XuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Richard J GuminaDepartment of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210, USA.
Shan-Lu LiuCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University · USThe Ohio State University Wexner Medical Center · US

Funding

Project 3: Responding to Changing Serological and Viral Information around COVID-19 (RESPOND)U54CA260582 · NCI · OHIO STATE UNIVERSITY · PI MCALEARNEY, ANN SCHECK, OLTZ, EUGENE M · 2020 to 2024
$10.4M
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infectionsR01HD095881 · NICHD · OHIO STATE UNIVERSITY · PI SAIF, LINDA J., VLASOVA, ANASTASIA NICKOLAEVNA · 2018 to 2022
$2.3M
NCI NIH HHS U54 CA260582NICHD NIH HHS R01 HD095881
6 · The paper itself

Abstract

Newly emerging Omicron subvariants continue to emerge around the world, presenting potential challenges to current vaccination strategies. This study investigates the extent of neutralizing antibody escape by new subvariants XBB.1.5, CH.1.1, and CA.3.1, as well as their impacts on spike protein biology. Our results demonstrated a nearly complete escape of these variants from neutralizing antibodies stimulated by three doses of mRNA vaccine, but neutralization was rescued by a bivalent booster. However, CH.1.1 and CA.3.1 variants were highly resistant to both monovalent and bivalent mRNA vaccinations. We also assessed neutralization by sera from individuals infected during the BA.4/5 wave of infection and observed similar trends of immune escape. In these cohorts, XBB.1.5 did not exhibit enhanced neutralization resistance over the recently dominant BQ.1.1 variant. Notably, the spike proteins of XBB.1.5, CH.1.1, and CA.3.1 all exhibited increased fusogenicity compared to BA.2, correlating with enhanced S processing. Overall, our results support the administration of new bivalent mRNA vaccines, especially in fighting against newly emerged Omicron subvariants, as well as the need for continued surveillance of Omicron subvariants.

Identifiers

PMID36711991
PMCPMC9882202
OpenAlexW4317392261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.